Carisbamate vs Oxcarbazepine (Oxtellar XR)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Epilepsy

Shared mechanism: Voltage-gated sodium channel · full Epilepsy pipeline

Carisbamate

Developed by SK Biopharmaceuticals Co., Ltd.

Phase 3 in Epilepsysmall molecule
Partial signal

NCT00425282 · Phase 3 · completed

This randomized, double-blind, placebo-controlled Phase 3 study (study 1 of two identical trials) gave carisbamate 200 or 400 mg/day or placebo for 12 weeks to 565 adults with refractory partial-onset seizures. The registered primary endpoint was the change in partial-onset seizure frequency. The 400 mg/day dose met it (median reduction 27.27% vs 15.21% with placebo, P = 0.009, and the paper reports the responder rate was also significant at this dose), while 200 mg/day did not differ from placebo (P = 0.678). The primary endpoint was met at the higher dose and missed at the lower dose, so the result is mixed. Sources: EU Clinical Trials Register results (EudraCT 2006-003839-68) and Sperling et al., Epilepsia 2010.

Next expected readout: February 2027 · NCT05219617 (registry estimate)

Reported efficacy

The primary outcome is the change in seizure frequency of all simple partial motor, complex partial, or secondarily generalized seizures from the pretreatment baseline phase compared with the double-blind treatment phase.: Primary endpoint, median percent reduction in partial-onset seizure frequency (double-blind phase vs baseline, ITT): carisbamate 400 mg/day 27.27% (n=191) vs placebo 15.21% (n=183), P = 0.009; carisbamate 200 mg/day 16.44% (n=187), P = 0.678 vs placebo (pre-specified Wilcoxon rank sum tests, EU Clinical Trials Register results). (mixed)

Result source: NCT00425282

Oxcarbazepine (Oxtellar XR)

Marketed by Supernus Pharmaceuticals

Approved in Epilepsysmall molecule
Partial signal

NCT00772603 · Phase 3 · completed

The trial was randomized, quadruple-blind, placebo-controlled, and included 366 participants, with seizure frequency as a clinical primary endpoint. The 2,400-mg comparison significantly favored oxcarbazepine, while the 1,200-mg comparison did not, so the primary result was mixed rather than consistently positive.

Reported efficacy

Percent Change in Seizure Rate (one year): Percent Change in Seizure Rate (one year): Oxcarbazepine XR -26.3 percentage of change in seizure rate (range -100 to 344.7) (not_applicable)

Result source: NCT00908349

Results for Epilepsy

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointCarisbamateOxcarbazepine (Oxtellar XR)
Seizure frequency, % change—Not posted · NCT00433667—Not reported
50% responder rate—Not posted · NCT0043366750% vs 34%+16 vs placebo2400 mg/day · wk 16 · n 109NCT00772603
1 other result
  • 44% vs 34% 1200 mg/day · wk 16 · n 111 · Phase 3 · secondary NCT00772603
Seizure freedom—Not posted · NCT00433667—Not reported

Seizure frequency, % change

Carisbamate
—Not posted · NCT00433667
Oxcarbazepine (Oxtellar XR)
—Not reported

50% responder rate

Carisbamate
—Not posted · NCT00433667
Oxcarbazepine (Oxtellar XR)
50% vs 34%+16 vs placebo2400 mg/day · wk 16 · n 109NCT00772603
1 other result
  • 44% vs 34% 1200 mg/day · wk 16 · n 111 · Phase 3 · secondary NCT00772603

Seizure freedom

Carisbamate
—Not posted · NCT00433667
Oxcarbazepine (Oxtellar XR)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Carisbamate
Primary endpoint, median percent reduction in partial-onset seizure frequency (double-blind phase vs baseline, ITT): carisbamate 400 mg/day 27.27% (n=191) vs placebo 15.21% (n=183), P = 0.009; carisbamate 200 mg/day 16.44% (n=187), P = 0.678 vs placebo (pre-specified Wilcoxon rank sum tests, EU Clinical Trials Register results). NCT00425282 · Phase 3 · design grade: moderate · publication or press release
Primary endpoint, responder rate (at least 50% reduction in partial-onset seizure frequency, double-blind phase vs baseline): carisbamate 400 mg 23.8% and 200 mg 23.1% vs placebo 21.3%; difference 2.48 points (95% CI -6.04 to 11), P = 0.553 (400 mg) and 1.84 points (95% CI -6.58 to 10.26), P = 0.637 (200 mg) (pre-specified CMH tests, EU Clinical Trials Register results). NCT00433667 · Phase 3 · design grade: moderate · publication or press release

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Carisbamate: 0 of 4 rows · Oxcarbazepine (Oxtellar XR): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricOxcarbazepine (Oxtellar XR)
Dropout rate
42.3%2400 mg/daya
NCT00772603 · Phase 3 · Epilepsy · phase 3
show 2 more results
32.8%1200 mg/day
NCT00772603 · Phase 3 · Epilepsy · phase 3
16.4%
NCT00908349 · Phase 3 · monotherapy
Discontinued due to AEs
30.1%2400 mg/daya
NCT00772603 · Phase 3 · Epilepsy · phase 3
show 2 more results
14.8%1200 mg/day
NCT00772603 · Phase 3 · Epilepsy · phase 3
4.7%
NCT00908349 · Phase 3 · monotherapy
Serious AEs
8.1%2400 mg/daya
NCT00772603 · Phase 3 · Epilepsy · phase 3
show 2 more results
5.7%1200 mg/day
NCT00772603 · Phase 3 · Epilepsy · phase 3
8.4%
NCT00908349 · Phase 3 · monotherapy
Most frequent reported AEs
2400 mg/daya
dizziness 40.7% (placebo 14.9%)
headache 15.4% (placebo 7.4%)
vomiting 15.4% (placebo 9.1%)
NCT00772603 · Phase 3 · Epilepsy · phase 3
show 2 more results
1200 mg/day
dizziness 19.7% (placebo 14.9%)
somnolence 11.5% (placebo 9.1%)
diplopia 9.8% (placebo 4.1%)
NCT00772603 · Phase 3 · Epilepsy · phase 3
dizziness 15.4%
headache 11.2%
diplopia 9.3%
NCT00908349 · Phase 3 · monotherapy

Notes

  1. aPopulation comparability has not been reviewed for 1 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Oxcarbazepine (Oxtellar XR)

Seizure 50 50% (n=109) vs 34% (n=117) placebo @ 16wk2400 mg/day
responder rate · % of participants
NCT00772603 · Phase 3 · Epilepsy · phase 3
show 1 more result
44% (n=111) vs 34% (n=117) placebo @ 16wk1200 mg/day
NCT00772603 · Phase 3 · Epilepsy · phase 3
Seizure Free 14% (n=111) vs 4% (n=117) placebo @ 16wk2400 mg/day
absolute value · percentage points
NCT00772603 · Phase 3 · Epilepsy · phase 3
show 1 more result
6% (n=109) vs 4% (n=117) placebo @ 16wk1200 mg/day
NCT00772603 · Phase 3 · Epilepsy · phase 3
Seizure Free 17% (n=88) vs 7% (n=109) placebo @ 12wk2400 mg/day
absolute value · percentage points
Maintenance
NCT00772603 · Phase 3 · Epilepsy · phase 3
show 1 more result
4% (n=97) vs 7% (n=109) placebo @ 12wk1200 mg/day
NCT00772603 · Phase 3 · Epilepsy · phase 3

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Carisbamate's landscape · Oxcarbazepine (Oxtellar XR)'s landscape